Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.

Thumbnail
View/Open
Accepted version (933.8Kb)
Date
2020-07
ICR Author
Lopez, Juanita
Yap, Christina
De Bono, Johann
Banerji, Udai
Author
Tiu, C
Shinde, R
Yap, C
Rao Baikady, B
Banerji, U
Minchom, AR
de Bono, JS
Lopez, JS
Show allShow less
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/3801
DOI
https://doi.org/10.1016/s1470-2045(20)30339-9
Collections
  • Cancer Therapeutics
  • Clinical Studies
Subject
Humans
Pneumonia, Viral
Coronavirus Infections
Neoplasms
Antiviral Agents
Risk Assessment
Clinical Trials, Phase I as Topic
Pandemics
United Kingdom
Betacoronavirus
Data Management
COVID-19
SARS-CoV-2
Research team
Medicine (de Bono Prostate)
Clinical Pharmacology – Adaptive Therapy
Clinical Trials & Statistics Unit
Prostate Cancer Targeted Therapy Group
Language
eng
Date accepted
2020-05-27
License start date
2020-07
Citation
The Lancet. Oncology, 2020, 21 (7), pp. 889 - 891

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.